Slingshot members are tracking this event:
Celgene (CELG) 2018 data readout for Phase 3 OPTIMISM trial, testing POMALYST and IMNOVID in patients with relapsed refractory myeloma
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|CELG||Community voting in process|
Slingshot Insights Explained
Feb 06, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Pomalyst, Imnovid, Relapsed Multiple Myeloma, Optimism, Phase 3